Rituximab for refractory focal segmental glomerulosclerosis

Makiko Nakayama, Koichi Kamei, Kandai Nozu, Kentaro Matsuoka, Atsuko Nakagawa, Mayumi Sako, Kazumoto Iijima

Research output: Contribution to journalArticlepeer-review

80 Citations (Scopus)


We present the cases of two children with steroid-resistant nephrotic syndrome (SRNS) who were treated with rituximab (anti-CD20 monoclonal antibody). Both were resistant to conventional therapy, and renal biopsy showed focal segmental glomerulosclerosis (FSGS). Combination therapy with methylprednisolone pulse therapy and plasmapheresis was the only way to decrease proteinuria. However, the patients suffered severe reactions to steroid treatment. We therefore treated them with rituximab in a single dose of 375 mg/m2, which resulted in the rapid clearing of circulating CD19-positive B cells. One month after rituximab treatment, both achieved partial remission; one patient has maintained complete remission for 8 months, and the other relapsed 8 months after the first rituximab treatment with the recovery of peripheral B-cell counts and received a second rituximab treatment. She achieved complete remission 5 months after the second course and has maintained the remission for 2 months. We conclude that rituximab may be an effective treatment for refractory SRNS with FSGS.

Original languageEnglish
Pages (from-to)481-485
Number of pages5
JournalPediatric Nephrology
Issue number3
Publication statusPublished - 2008 Mar
Externally publishedYes


  • B cells
  • Focal segmental glomerulosclerosis
  • Plasmapheresis
  • Rituximab
  • Steroid-resistant nephrotic syndrome

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Nephrology


Dive into the research topics of 'Rituximab for refractory focal segmental glomerulosclerosis'. Together they form a unique fingerprint.

Cite this